An Australian AI consultant used ChatGPT, AlphaFold, and Grok to find a possible treatment for his dog Rosie’s incurable cancer. The story went viral after high-profile AI executives like OpenAI’s Greg Brockman and Deepmind’s Demis Hassabis shared it as proof of what AI can already do. But there’s no evidence the AI-designed vaccine actually worked.
Eli Lilly has signed a $2.75 billion deal with Hong Kong-listed AI pharmaceutical company Insilico Medicine. The partnership aims to bring AI-developed drugs to the global market. Insilico will receive $115 million upfront, with the rest tied to regulatory and commercial milestones as well as license fees, both companies announced.
According to founder and CEO Alex Zhavoronkov, Insilico has developed at least 28 drugs using generative AI, with nearly half already in clinical trials. The two companies have been working together since 2023.
Zhavoronkov told CNBC that Lilly actually outperforms Insilico in some areas of AI. Andrew Adams of Lilly called Insilico's AI research "a powerful complement" to its own clinical development efforts. Insilico is building its AI capabilities in Canada and the Middle East, while early drug development takes place in China. Eli Lilly is also working with a Deepmind subsidiary on AI-driven medicine.
AI models tell people what they want to hear nearly 50 percent more often than other humans do. A new Science study shows this isn’t just annoying: it makes people less willing to apologize, less likely to see the other side, and more convinced they’re right. The worst part: users love it.
Google has built an "Agent Skill" for the Gemini API that tackles a fundamental problem with AI coding assistants: once trained, language models don't know about their own updates or current best practices. The new skill feeds coding agents up-to-date information about current models, SDKs, and sample code. In tests across 117 tasks, the top-performing model (Gemini 3.1 Pro Preview) jumped from 28.2 to 96.6 percent success rate. Skills were first introduced late last year by Anthropic and quickly adopted by other AI companies.
Older 2.5 models saw much smaller improvements, which Google says comes down to weaker reasoning abilities. Interestingly, a Vercel study suggests that giving models direct instructions through AGENTS.md files could be even more effective. Google is exploring other approaches as well, including MCP services. The skill is available on GitHub.
Anthropic grew out of more than just concern for AI safety—it was born from a bitter power struggle and personal conflict at OpenAI. A report by Sam Altman biographer Keach Hagey reveals how personal slights, rivalries, and strategic disagreements led to what may be the most consequential split in the AI industry.
OpenAI is killing Sora in two stages. The web and app version goes dark on April 26, 2026, with the Sora API following on September 24, 2026. OpenAI is urging users to download their content before the cutoff dates. Videos and images can be exported directly from the Sora library.
The company says it hasn't decided yet whether there will be a final export window after those dates. If one happens, users will get an email heads-up. Once all deadlines pass, user data gets permanently deleted. The shutdown also takes down the sora.chatgpt.com platform, which handled image and video generation. Full details are on OpenAI's help page under "What to know about the Sora discontinuation."
Sora's demise is part of a bigger strategic pivot. OpenAI wants to funnel compute toward coding tools and enterprise customers—a play that mirrors rival Anthropic—and a super app rolling ChatGPT and other tools into one package. Sora will stick around as a research project focused on world models, with the long-term goal of "automating the physical economy."
